drugset
drugset / Trial / NCT00347646

A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

NCT00347646 ↗

Phase 1/2 Terminated 4 enrolled Bausch & Lomb Incorporated
NaSingle-groupOpen-labelTreatment

Summary

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.

Timeline

Start
2006-09
Primary completion
2007-05
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Plasmin Protein / enzyme biologic 27 mg Intravitreal

Indications

vitreoretinal degeneration